SCPH — SCPHARMACEUTICALS INC

Ownership history in UBS Group AG  ·  28 quarters on record

This page tracks every 13F SEC filing in which UBS Group AG reported a position in SCPHARMACEUTICALS INC (SCPH). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 117,255 -738,047 -86.3% 0.00% $665K —
2025 Q2 ADDED 855,302 +527,887 +161.2% 0.00% $3.3M —
2025 Q1 REDUCED 327,415 -709,864 -68.4% 0.00% $861K —
2024 Q4 ADDED 1,037,279 +1,017,775 +5218.3% 0.00% $3.7M —
24 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)

Other funds also holding SCPH

As of 2025 Q3 — sorted by position size

Yakira Capital Management, Inc. 3Y 7Y 0.87% ORBIMED ADVISORS LLC 3Y 7Y 0.81% Tejara Capital Ltd 3Y 0.73% Newtyn Management, LLC 3Y 7Y 0.65% APIS CAPITAL ADVISORS, LLC 3Y 7Y 0.55% Rangeley Capital, LLC 0.46% Balanced Rock Investment Advisors LLC 0.34% ALPINE ASSOCIATES MANAGEMENT INC. 3Y 7Y 0.33% Rubric Capital Management LP 3Y 7Y 0.33% GABELLI & Co INVESTMENT ADVISERS, INC. 3Y 7Y 0.28%
← Back to UBS Group AG Holdings